{"pmid":32328234,"pmcid":"PMC7163230","title":"Does the direct renin inhibitor have a role to play in attenuating severity of the outbreak coronavirus disease 2019 (COVID-19)?","text":["Does the direct renin inhibitor have a role to play in attenuating severity of the outbreak coronavirus disease 2019 (COVID-19)?","Ther Adv Endocrinol Metab","Lin, Cheng-Wei","Huang, Yu-Yao","32328234"],"journal":"Ther Adv Endocrinol Metab","authors":["Lin, Cheng-Wei","Huang, Yu-Yao"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32328234","week":"202017|Apr 20 - Apr 26","doi":"10.1177/2042018820916430","keywords":["2019-ncov","covid-19","angiotensin-converting enzyme 2","direct renin inhibitor"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664996914760777728,"score":8.518259,"similar":[{"pmid":32286607,"title":"Might renin-angiotensin system blockers play a role in the COVID-19 pandemic?","text":["Might renin-angiotensin system blockers play a role in the COVID-19 pandemic?","Since December 2019, a new coronavirus, named SARS-CoV-2, has spread globally, affecting >200 000 people worldwide with the so-called COVID-19 disease. The scientific community is actively and constantly working to identify the mechanisms involved in the diffusion of this virus and the pathogenesis of the infection, with its most frequent and severe complication, namely interstitial pneumonia. To date, SARS-CoV-2 is known to enter the host cells via the angiotensin-converting enzyme 2 protein. For this reason, the hypothesis that drugs capable of increasing the expression of this protein may have a role in the spread of the virus and in the symptomatology of affected patients has taken hold. The purpose of this Editorial is to briefly show the evidence currently available in this regard and to provide ideas for future research.","Eur Heart J Cardiovasc Pharmacother","Battistoni, Allegra","Volpe, Massimo","32286607"],"abstract":["Since December 2019, a new coronavirus, named SARS-CoV-2, has spread globally, affecting >200 000 people worldwide with the so-called COVID-19 disease. The scientific community is actively and constantly working to identify the mechanisms involved in the diffusion of this virus and the pathogenesis of the infection, with its most frequent and severe complication, namely interstitial pneumonia. To date, SARS-CoV-2 is known to enter the host cells via the angiotensin-converting enzyme 2 protein. For this reason, the hypothesis that drugs capable of increasing the expression of this protein may have a role in the spread of the virus and in the symptomatology of affected patients has taken hold. The purpose of this Editorial is to briefly show the evidence currently available in this regard and to provide ideas for future research."],"journal":"Eur Heart J Cardiovasc Pharmacother","authors":["Battistoni, Allegra","Volpe, Massimo"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32286607","week":"202016|Apr 13 - Apr 19","doi":"10.1093/ehjcvp/pvaa030","keywords":["hypertension","ras system","sars-cov-2"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664636391597801473,"score":112.79556},{"pmid":32286678,"title":"Inhibitors of the renin-angiotensin system: The potential role in the pathogenesis of COVID-19.","text":["Inhibitors of the renin-angiotensin system: The potential role in the pathogenesis of COVID-19.","Coronavirus disease 2019 (COVID-19), which initially began in China, has spread to other countries of Asia, Europe, America, Africa and Oceania, with the number of confirmed cases and suspected cases increasing each day. According to recently published research, it was found that the majority of the severe cases were elderly, and many of them had at least one chronic disease, especially cardiovascular diseases. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs) are the most widely used drugs for cardiovascular diseases. The clinical effect of ACEIs/ARBs on patients with COVID-19 is still uncertain. This paper describes their potential role in the pathogenesis of COVID-19, which may provide useful in the advice of cardiologists and physicians.","Cardiol J","Huang, Ziyin","Jiang, Yufeng","Chen, Jingjing","Zhou, Yafeng","32286678"],"abstract":["Coronavirus disease 2019 (COVID-19), which initially began in China, has spread to other countries of Asia, Europe, America, Africa and Oceania, with the number of confirmed cases and suspected cases increasing each day. According to recently published research, it was found that the majority of the severe cases were elderly, and many of them had at least one chronic disease, especially cardiovascular diseases. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs) are the most widely used drugs for cardiovascular diseases. The clinical effect of ACEIs/ARBs on patients with COVID-19 is still uncertain. This paper describes their potential role in the pathogenesis of COVID-19, which may provide useful in the advice of cardiologists and physicians."],"journal":"Cardiol J","authors":["Huang, Ziyin","Jiang, Yufeng","Chen, Jingjing","Zhou, Yafeng"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32286678","week":"202016|Apr 13 - Apr 19","doi":"10.5603/CJ.a2020.0056","keywords":["2019-ncov","covid-19","angiotensin-converting enzyme inhibitors","renin-angiotensin system"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"locations":["China","America"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664636391618772992,"score":110.628136},{"pmid":32233755,"title":"Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.","text":["Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.","J Am Heart Assoc","Guo, Junyi","Huang, Zheng","Lin, Li","Lv, Jiagao","32233755"],"journal":"J Am Heart Assoc","authors":["Guo, Junyi","Huang, Zheng","Lin, Li","Lv, Jiagao"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32233755","week":"202014|Mar 30 - Apr 05","doi":"10.1161/JAHA.120.016219","keywords":["acei/arb","covid-19","sars-cov-2","angiotensin-converting enzyme 2","cardiovascular disease"],"link_comment_for":"32233753","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["Onset"],"_version_":1664638354125225985,"score":108.17226},{"pmid":32215613,"title":"Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System-a Call for Epidemiologic Investigations.","text":["Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System-a Call for Epidemiologic Investigations.","Mortality from coronavirus disease 2019 (COVID-19) is strongly associated with cardiovascular disease, diabetes, and hypertension. These disorders share underlying pathophysiology related to the renin-angiotensin system (RAS) that may be clinically insightful. In particular, activity of the angiotensin-converting enzyme 2 (ACE2) is dysregulated in cardiovascular disease, and this enzyme is used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to initiate the infection. Cardiovascular disease and pharmacologic RAS inhibition both increase ACE2 levels, which may increase the virulence of SARS-CoV-2 within the lung and heart. Conversely, mechanistic evidence from related coronaviruses suggests that SARS-CoV-2 infection may downregulate ACE2, leading to toxic overaccumulation of Angiotensin II that induces acute respiratory distress syndrome and fulminant myocarditis. RAS inhibition could mitigate this effect. With conflicting mechanistic evidence, we propose key clinical research priorities necessary to clarify the role of RAS inhibition in COVID-19 mortality that could be rapidly addressed by the international research community.","Clin Infect Dis","Hanff, Thomas C","Harhay, Michael O","Brown, Tyler S","Cohen, Jordana B","Mohareb, Amir M","32215613"],"abstract":["Mortality from coronavirus disease 2019 (COVID-19) is strongly associated with cardiovascular disease, diabetes, and hypertension. These disorders share underlying pathophysiology related to the renin-angiotensin system (RAS) that may be clinically insightful. In particular, activity of the angiotensin-converting enzyme 2 (ACE2) is dysregulated in cardiovascular disease, and this enzyme is used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to initiate the infection. Cardiovascular disease and pharmacologic RAS inhibition both increase ACE2 levels, which may increase the virulence of SARS-CoV-2 within the lung and heart. Conversely, mechanistic evidence from related coronaviruses suggests that SARS-CoV-2 infection may downregulate ACE2, leading to toxic overaccumulation of Angiotensin II that induces acute respiratory distress syndrome and fulminant myocarditis. RAS inhibition could mitigate this effect. With conflicting mechanistic evidence, we propose key clinical research priorities necessary to clarify the role of RAS inhibition in COVID-19 mortality that could be rapidly addressed by the international research community."],"journal":"Clin Infect Dis","authors":["Hanff, Thomas C","Harhay, Michael O","Brown, Tyler S","Cohen, Jordana B","Mohareb, Amir M"],"date":"2020-03-28T11:00:00Z","year":2020,"_id":"32215613","week":"202013|Mar 23 - Mar 29","doi":"10.1093/cid/ciaa329","keywords":["angiotensin-converting enzyme 2","covid-19","cardiovascular disease","renin-angiotensin system","sars-cov-2"],"source":"PubMed","topics":["Mechanism"],"weight":1,"_version_":1664638838245425152,"score":93.02706},{"pmid":32333969,"title":"Response to COVID -19 and Diabetes: Can DPP4 Inhibition Play a Role? - GLP-1 Might Play One Too.","text":["Response to COVID -19 and Diabetes: Can DPP4 Inhibition Play a Role? - GLP-1 Might Play One Too.","Diabetes Res Clin Pract","Morin, Nathaniel","32333969"],"journal":"Diabetes Res Clin Pract","authors":["Morin, Nathaniel"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333969","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.diabres.2020.108160","keywords":["covid","glucagon like peptide 1 (glp-1)","hyperglycemia","interleukin 6 (il-6)"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1665071049731997696,"score":90.22222}]}